As COMPASS Pathways (NASDAQ:CMPS) crunches more data from a recent trial investigating psilocybin therapy for treatment-resistant depression (TRD), findings show that a higher dose of 25mg (compared ...
In terms of prognostic risk factors, HER2 positivity, BM surgical resection, and diagnosis after 2014 were associated with ...
This study advances the current literature investigating the relationship between contextual out-group exposure, inter-group attitudes and the role of inter-group contact. Firstly, it introduces the ...
Results of COMPASS Pathways’ open-label study of COMP360 psilocybin treatment, alongside SSRI antidepressants, suggest that SSRIs do not interfere with the potential therapeutic effect of COMP360 The ...
Sometimes in our lives, we might be haunted by our inner voice that fills our minds with doubt and harsh criticisms, manifesting feelings of worthlessness that we are not good enough. This human ...
Positron emission tomography (PET) and estrogen receptor (ER) ligand in patients with invasive breast cancer. Germline single nucleotide polymorphisms (SNPs) in XRCC3, XRCC1, and XPD, and survival ...
Hosted on MSN
Compass Pathways Stock Slumps After Positive Late-Stage Trial Results From Psychedelic Drug ‘Underwhelm’ Analysts
Shares of Compass Pathways Plc. (CMPS) slumped 47% on Monday afternoon after the results from the late-stage trials of COMP360 in treatment-resistant depression fell short of market expectations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback